Zithromax (azithromycin) was linked to two patients back in 2006, and is thought to carry a small risk for a condition that starts - as SJS often does - with a Zithromax rash. The US Food and Drug Administration (FDA) had a more recent bone to pick with Zithromax manufacturer Pfizer when, in 2012, it took Pfizer to task for not being quite upfront enough in a brochure advertising Zmax, an extended-release version of Zithromax, with regard to the potential severity of such Zithromax reactions.
Little Oakley Orange’s story is a testament to that severity, and just how dangerous and devastating Stevens Johnson Syndrome can be.
As chronicled in KentOnline (1/11/14), Oakley developed a rash in early December after taking a prescribed medication for 12 days. Within 24 hours, according to his parents, their son quickly became unrecognizable. Blisters the size of golf balls began to form, and before long entire lengths of skin - the upper dermas - began to slough away.
Even worse, according to the report, was the fact that Oakley’s SJS quickly degenerated to Toxic Epidermal Necrolysis, or TENS, the most serious form of Stevens Johnson Syndrome. A patient is thought to suffer from TENS when 30 percent or more of the upper layer of skin has been lost.
In Oakley’s case, it was 100 percent skin loss. The boy was given just a 65 percent chance of survival. At one point, said his mother Lorraine, they thought to have lost him “when his temperature plummeted and he was diagnosed with hypothermia. But the doctors have been able to warm him up. After Friday I think he can fight through anything.
“It is the most horrific thing for a parent to have to see their child suffer in the way Oakley has,” Lorraine Orange told KentOnline.
READ MORE ZITHROMAX SJS LEGAL NEWS
“I want to educate as many people as I can about SJS,” Lorraine Orange told KentOnline. “This can happen with any medication, not just what Oakley was taking. You need to read the leaflet and make sure your child is not sensitive to anything.”
One must also make sure the leaflet is sufficiently thorough in divesting the necessary information about risks, something that the FDA said didn’t happen with the Zmax leaflet by way of its 2012 communication with Pfizer. The risks for Zithromax SJS are too compelling to ignore…